JP2012532888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532888A5 JP2012532888A5 JP2012519764A JP2012519764A JP2012532888A5 JP 2012532888 A5 JP2012532888 A5 JP 2012532888A5 JP 2012519764 A JP2012519764 A JP 2012519764A JP 2012519764 A JP2012519764 A JP 2012519764A JP 2012532888 A5 JP2012532888 A5 JP 2012532888A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidin
- pyrazolo
- carboxamide
- pyrimidine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 254
- 150000001875 compounds Chemical class 0.000 claims description 104
- -1 2,5-difluorophenyl Chemical group 0.000 claims description 95
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- XMRIUEGHBZTNND-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=NC2=C(C(=O)N)C=NN21 XMRIUEGHBZTNND-UHFFFAOYSA-N 0.000 claims 47
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 3
- UEHKWTJSMNTTCC-SJKOYZFVSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-N-[(2R)-2-hydroxypropyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@@H](O)CNC(=O)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 UEHKWTJSMNTTCC-SJKOYZFVSA-N 0.000 claims 2
- CYJPVTPYPTUQAC-HYSRAYMDSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-(4-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(C)(O)CCC1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 CYJPVTPYPTUQAC-HYSRAYMDSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- LJCJRRKKAKAKRV-UHFFFAOYSA-N (2-amino-2-methylpropyl) 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical group CC(C)(N)COC(=O)CCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 LJCJRRKKAKAKRV-UHFFFAOYSA-N 0.000 claims 1
- GNFIVOXDMLGGJJ-MRXNPFEDSA-N 1-[2-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazol-1-yl]ethyl]imidazolidin-2-one Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=CC=NN1CCN1C(NCC1)=O GNFIVOXDMLGGJJ-MRXNPFEDSA-N 0.000 claims 1
- PFTUHNICIXICMP-LJQANCHMSA-N 1-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 PFTUHNICIXICMP-LJQANCHMSA-N 0.000 claims 1
- HUMIANOGLZOVBP-MRXNPFEDSA-N 1-[[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonyl]amino]cyclopropane-1-carboxylic acid Chemical compound C1=NN2C=CC(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)=NC2=C1C(=O)NC1(C(=O)O)CC1 HUMIANOGLZOVBP-MRXNPFEDSA-N 0.000 claims 1
- BNDQCVSMOIBZCI-GOSISDBHSA-N 1-cyclopropyl-5-[(2r)-2-[3-fluoro-5-(2-methoxyethoxy)phenyl]pyrrolidin-1-yl]pyrazole Chemical compound COCCOC1=CC(F)=CC([C@@H]2N(CCC2)C=2N(N=CC=2)C2CC2)=C1 BNDQCVSMOIBZCI-GOSISDBHSA-N 0.000 claims 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- HYQUCWQCNZSJRP-HXUWFJFHSA-N 2-[1-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonyl]piperidin-4-yl]acetic acid Chemical compound C1CC(CC(=O)O)CCN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 HYQUCWQCNZSJRP-HXUWFJFHSA-N 0.000 claims 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 claims 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 claims 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- ZZZONOLAOQEATF-QGZVFWFLSA-N 4-[[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazol-1-yl]methyl]-1-methylimidazole Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=CC=NN1CC=1N=CN(C=1)C ZZZONOLAOQEATF-QGZVFWFLSA-N 0.000 claims 1
- YYWBCTXPSKWIQX-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-1-[2-(1H-imidazol-5-yl)ethyl]pyrazole Chemical compound N1C=NC(=C1)CCN1N=CC=C1N1[C@H](CCC1)C1=C(C=CC(=C1)F)F YYWBCTXPSKWIQX-QGZVFWFLSA-N 0.000 claims 1
- WGQPLEIMNLEFTL-QGZVFWFLSA-N 5-[(2R)-2-(5-fluoro-1-methyl-2-oxopyridin-3-yl)pyrrolidin-1-yl]-N-(5-hydroxypyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CN1C=C(F)C=C([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)NC2=NC=C(O)C=C2)C1=O WGQPLEIMNLEFTL-QGZVFWFLSA-N 0.000 claims 1
- OTCSCPHWCZZRDC-LBXVMSDZSA-N 5-[(2R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-N-(4-methylsulfonylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@H]1CCCN1C1=NC2=C(C=NN2C=C1)C(=O)NC1CCC(CC1)S(C)(=O)=O OTCSCPHWCZZRDC-LBXVMSDZSA-N 0.000 claims 1
- DUJWGLCTYAWISR-MRXNPFEDSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n,n-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N(C)C)=CC(F)=CC=C1F DUJWGLCTYAWISR-MRXNPFEDSA-N 0.000 claims 1
- XWDLDVQSUXONBG-LJQANCHMSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-(3-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC=CN=C1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 XWDLDVQSUXONBG-LJQANCHMSA-N 0.000 claims 1
- IXPTZPMMOJWPBZ-JBBXEZCESA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2r,3s)-1,3-dihydroxybutan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@H](CO)[C@@H](O)C)=CC(F)=CC=C1F IXPTZPMMOJWPBZ-JBBXEZCESA-N 0.000 claims 1
- PXRHKVCFGOFIIB-SUMWQHHRSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s)-2,3-dihydroxypropoxy]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC[C@@H](O)CO)=CC(F)=CC=C1F PXRHKVCFGOFIIB-SUMWQHHRSA-N 0.000 claims 1
- GSSDAQWHOJFZRE-SUMWQHHRSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s)-2,3-dihydroxypropyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC[C@H](O)CO)=CC(F)=CC=C1F GSSDAQWHOJFZRE-SUMWQHHRSA-N 0.000 claims 1
- IXPTZPMMOJWPBZ-OCBCSQNSSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s,3r)-1,3-dihydroxybutan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@@H](CO)[C@H](O)C)=CC(F)=CC=C1F IXPTZPMMOJWPBZ-OCBCSQNSSA-N 0.000 claims 1
- IXPTZPMMOJWPBZ-UYHISHBKSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s,3s)-1,3-dihydroxybutan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@@H](CO)[C@@H](O)C)=CC(F)=CC=C1F IXPTZPMMOJWPBZ-UYHISHBKSA-N 0.000 claims 1
- OMWFIVWGJYQGKO-GOSISDBHSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[1-(methanesulfonamido)-2-methylpropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(CNS(C)(=O)=O)C)=CC(F)=CC=C1F OMWFIVWGJYQGKO-GOSISDBHSA-N 0.000 claims 1
- FUHAANUNQWUCBT-OAHLLOKOSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CC(F)=CC=C1F FUHAANUNQWUCBT-OAHLLOKOSA-N 0.000 claims 1
- MBZCRLUONJJYJU-OAHLLOKOSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC(F)=CC=C1F MBZCRLUONJJYJU-OAHLLOKOSA-N 0.000 claims 1
- JBTQGTQNCVBRNY-CQSZACIVSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1F JBTQGTQNCVBRNY-CQSZACIVSA-N 0.000 claims 1
- PEUXFCOIQKEZCE-CQSZACIVSA-N 5-[(2r)-2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(2-hydroxyethoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOCCO)=CC(F)=CN=C1Cl PEUXFCOIQKEZCE-CQSZACIVSA-N 0.000 claims 1
- CXFMNHBMKOIQLW-QGZVFWFLSA-N 5-[(2r)-2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[2-[(2-methylpropan-2-yl)oxy]ethoxy]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOCCOC(C)(C)C)=CC(F)=CN=C1Cl CXFMNHBMKOIQLW-QGZVFWFLSA-N 0.000 claims 1
- YFZGYNMBIQOANX-TWOQFEAHSA-N 5-[(2r)-2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[(1s,3s)-3-hydroxycyclopentyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CCC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N[C@@H]4C[C@@H](O)CC4)C=NN3C=C2)CCC1 YFZGYNMBIQOANX-TWOQFEAHSA-N 0.000 claims 1
- ISGDOVGHVRHZFY-AFMYVXGZSA-N 5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(O)CCC1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=CC=3)C=CN2N=C1 ISGDOVGHVRHZFY-AFMYVXGZSA-N 0.000 claims 1
- MLIFTZTWMYPZAL-OAHLLOKOSA-N 5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CC=CC(F)=C1 MLIFTZTWMYPZAL-OAHLLOKOSA-N 0.000 claims 1
- LZJSAQIUAQDIAJ-CQSZACIVSA-N 5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC=CC(F)=C1 LZJSAQIUAQDIAJ-CQSZACIVSA-N 0.000 claims 1
- GSRZAXNWBZUUOT-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-1-methyl-2-oxopyridin-3-yl)pyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CC(F)=CN(C)C1=O GSRZAXNWBZUUOT-MRXNPFEDSA-N 0.000 claims 1
- BBRVRCQHOJGIEM-QGZVFWFLSA-N 5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]-n-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCC(C)(C)O)C=NN3C=C2)CCC1 BBRVRCQHOJGIEM-QGZVFWFLSA-N 0.000 claims 1
- IHLOJSUOOQFANO-HXUWFJFHSA-N 5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]-n-(2-morpholin-4-ylethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCCN4CCOCC4)C=NN3C=C2)CCC1 IHLOJSUOOQFANO-HXUWFJFHSA-N 0.000 claims 1
- DCLFPTZRYFZAKO-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(1-fluoro-2-methylpropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC(C)(C)CF)C=NN3C=C2)CCC1 DCLFPTZRYFZAKO-MRXNPFEDSA-N 0.000 claims 1
- YLAKIDRGVDYWAA-OAHLLOKOSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(2-hydroxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCCO)C=NN3C=C2)CCC1 YLAKIDRGVDYWAA-OAHLLOKOSA-N 0.000 claims 1
- VTUVGNKQBUVKIW-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(3-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCCCO)C=NN3C=C2)CCC1 VTUVGNKQBUVKIW-MRXNPFEDSA-N 0.000 claims 1
- WRXZQYJJPXFOIB-LADRWXRNSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CCC(O)CC4)C=NN3C=C2)CCC1 WRXZQYJJPXFOIB-LADRWXRNSA-N 0.000 claims 1
- KUMKUBXRGRIPEY-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(5-methyl-1h-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC=4NN=C(C)C=4)C=NN3C=C2)CCC1 KUMKUBXRGRIPEY-MRXNPFEDSA-N 0.000 claims 1
- REPYLSGOOOJRSV-CQSZACIVSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CC(F)=CN=C1OC REPYLSGOOOJRSV-CQSZACIVSA-N 0.000 claims 1
- WAAWHVXSMHHZCZ-CQSZACIVSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC(F)=CN=C1OC WAAWHVXSMHHZCZ-CQSZACIVSA-N 0.000 claims 1
- XIDPBDLUUJOTDD-CYBMUJFWSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(N)=O)C=NN3C=C2)CCC1 XIDPBDLUUJOTDD-CYBMUJFWSA-N 0.000 claims 1
- AYXUQBNBYRQZDH-OAHLLOKOSA-N 5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC(F)=CN=C1C AYXUQBNBYRQZDH-OAHLLOKOSA-N 0.000 claims 1
- PMKFFRXMNWSTLH-QGZVFWFLSA-N 5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CC(F)=CN=C1C PMKFFRXMNWSTLH-QGZVFWFLSA-N 0.000 claims 1
- UEWLKIVHINNLJX-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C=CC(N3[C@H](CCC3)C=3C=C(F)C=NC=3)=NC2=C1C(=O)NC1(C)CC1 UEWLKIVHINNLJX-MRXNPFEDSA-N 0.000 claims 1
- LASRMRBYBVIFQT-LJQANCHMSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(1-methylsulfonylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 LASRMRBYBVIFQT-LJQANCHMSA-N 0.000 claims 1
- KJYXTMLZCPHUAV-IAQYHMDHSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[(2r)-1,1,1-trifluoropropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@H](C)C(F)(F)F)=CN=CC(F)=C1 KJYXTMLZCPHUAV-IAQYHMDHSA-N 0.000 claims 1
- ONENEBSQEBHUSO-CQSZACIVSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CN=CC(F)=C1 ONENEBSQEBHUSO-CQSZACIVSA-N 0.000 claims 1
- AOJFJIKCNFEJMA-CQSZACIVSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CN=CC(F)=C1 AOJFJIKCNFEJMA-CQSZACIVSA-N 0.000 claims 1
- KOZAUWSJLNLRBA-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CN=CC(F)=C1 KOZAUWSJLNLRBA-MRXNPFEDSA-N 0.000 claims 1
- LTWRCYLYOAZNPD-FQNRMIAFSA-N 5-[(2r)-2-[2-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1OCC(O)CO LTWRCYLYOAZNPD-FQNRMIAFSA-N 0.000 claims 1
- JDIGZDKHSLPKGP-KPMSDPLLSA-N 5-[(2r)-2-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(N)=O)C=NN3C=C2)CCC1 JDIGZDKHSLPKGP-KPMSDPLLSA-N 0.000 claims 1
- UGWUALPBTGHKQH-FBMWCMRBSA-N 5-[(2r)-2-[3-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC(OCC(O)CO)=C1 UGWUALPBTGHKQH-FBMWCMRBSA-N 0.000 claims 1
- QXACJSRSZMVUQK-WHCXFUJUSA-N 5-[(2r)-2-[3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC(F)=CC([C@@H]2N(CCC2)C2=NC3=C(C(N)=O)C=NN3C=C2)=C1 QXACJSRSZMVUQK-WHCXFUJUSA-N 0.000 claims 1
- OPRRDZXAVINFQM-MRXNPFEDSA-N 5-[(2r)-2-[5-fluoro-2-(2-methoxyethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COCCOC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(N)=O)C=NN3C=C2)CCC1 OPRRDZXAVINFQM-MRXNPFEDSA-N 0.000 claims 1
- CZZPKZAXQSRAJE-LJQANCHMSA-N 5-[(2r)-2-[5-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1OCCN1CCOCC1 CZZPKZAXQSRAJE-LJQANCHMSA-N 0.000 claims 1
- OVDQQFSDDWEASL-CQSZACIVSA-N 5-[(2r)-2-[5-fluoro-2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1C(F)(F)F OVDQQFSDDWEASL-CQSZACIVSA-N 0.000 claims 1
- TUPCMOPJDADTAY-UKRRQHHQSA-N 5-[(2r,4r)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2C[C@@H](O)CN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC=CC(F)=C1 TUPCMOPJDADTAY-UKRRQHHQSA-N 0.000 claims 1
- VEFAIJAFTRTKSA-DOTOQJQBSA-N 5-[(2r,4s)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2C[C@H](O)CN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CC=CC(F)=C1 VEFAIJAFTRTKSA-DOTOQJQBSA-N 0.000 claims 1
- HHFHBMCHRPJYLX-DOTOQJQBSA-N 5-[(2r,5s)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl]-n-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C=CC(N3[C@H](CC[C@H]3CO)C=3C=C(F)C=NC=3)=NC2=C1C(=O)NC1(C)CC1 HHFHBMCHRPJYLX-DOTOQJQBSA-N 0.000 claims 1
- AROVXDKGPGGRBP-DIOULYMOSA-N 5-[(2r,5s)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl]-n-[(2r)-1,1,1-trifluoropropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CC[C@@H](CO)N2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@H](C)C(F)(F)F)=CN=CC(F)=C1 AROVXDKGPGGRBP-DIOULYMOSA-N 0.000 claims 1
- JPAYSBNMHYNPLA-KRYHZZBUSA-N 5-[(2s,5r)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-n-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@@H]2N([C@](CC2)(C)CO)C=2C=CN3N=CC(=C3N=2)C(=O)N[C@@H](C)C(F)(F)F)=CN=CC(F)=C1 JPAYSBNMHYNPLA-KRYHZZBUSA-N 0.000 claims 1
- DYTJJBIQSYEXQH-UTKZUKDTSA-N 5-[(2s,5r)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@@H]2N([C@](CC2)(C)CO)C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CN=CC(F)=C1 DYTJJBIQSYEXQH-UTKZUKDTSA-N 0.000 claims 1
- RKVKRYPLPNWYSE-OAHLLOKOSA-N 5-[(5r)-5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCC(N2C2=NC3=C(C(N)=O)C=NN3C=C2)(C)C)=CC(F)=CC=C1F RKVKRYPLPNWYSE-OAHLLOKOSA-N 0.000 claims 1
- ZYIYWAPOCQBZSM-UHFFFAOYSA-N 5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[2-(4-hydroxypiperidin-1-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(O)CCN1CCNC(=O)C1=C2N=C(N3C(CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 ZYIYWAPOCQBZSM-UHFFFAOYSA-N 0.000 claims 1
- COJJJJKXTCQCLW-UHFFFAOYSA-N 5-[2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CCC1=NC=C(F)C=C1C1N(C2=NC3=C(C(=O)NC4CCC(O)CC4)C=NN3C=C2)CCC1 COJJJJKXTCQCLW-UHFFFAOYSA-N 0.000 claims 1
- GYPXDOPFEWTHRF-CTWPCTMYSA-N 5-[2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]-N-[(2R)-2-hydroxycyclopentyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=C(C=C(F)C=N1)C1CCCN1C1=NC2=C(C=NN2C=C1)C(=O)NC1CCC[C@H]1O GYPXDOPFEWTHRF-CTWPCTMYSA-N 0.000 claims 1
- RKRWQXHCILAOQU-UHFFFAOYSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(2-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OC1CCCC1NC(=O)C1=C2N=C(N3C(CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 RKRWQXHCILAOQU-UHFFFAOYSA-N 0.000 claims 1
- WWRZXXZWDNGWCD-UHFFFAOYSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(3-hydroxy-2,2-dimethylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N=1C2=C(C(=O)NCC(C)(CO)C)C=NN2C=CC=1N1CCCC1C1=CN=CC(F)=C1 WWRZXXZWDNGWCD-UHFFFAOYSA-N 0.000 claims 1
- CNSDQPQILIEBIM-UHFFFAOYSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(O)CCC1NC(=O)C1=C2N=C(N3C(CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 CNSDQPQILIEBIM-UHFFFAOYSA-N 0.000 claims 1
- RKRWQXHCILAOQU-GVYDCBATSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[(1r,2r)-2-hydroxycyclopentyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O[C@@H]1CCC[C@H]1NC(=O)C1=C2N=C(N3C(CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 RKRWQXHCILAOQU-GVYDCBATSA-N 0.000 claims 1
- DBAVNXWRJILFRQ-AKCHCHLHSA-N C1C[C@@H](C(=O)O)CC[C@@H]1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 Chemical compound C1C[C@@H](C(=O)O)CC[C@@H]1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 DBAVNXWRJILFRQ-AKCHCHLHSA-N 0.000 claims 1
- QILHXRYEOIFMNQ-OAQYLSRUSA-N CN1CCN(CCN2N(C=CC(N(CCC3)[C@H]3C(C=C(C=C3)F)=C3F)=N3)C3=CC2)CC1 Chemical compound CN1CCN(CCN2N(C=CC(N(CCC3)[C@H]3C(C=C(C=C3)F)=C3F)=N3)C3=CC2)CC1 QILHXRYEOIFMNQ-OAQYLSRUSA-N 0.000 claims 1
- ZQJUUOXBTWYBJE-QGZVFWFLSA-N [5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound C1C(C)(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 ZQJUUOXBTWYBJE-QGZVFWFLSA-N 0.000 claims 1
- OVSWBIYHLZFTTJ-QGZVFWFLSA-N [5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 OVSWBIYHLZFTTJ-QGZVFWFLSA-N 0.000 claims 1
- OKICNWNFGLYZRW-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N4CC(C)(O)C4)C=NN3C=C2)CCC1 OKICNWNFGLYZRW-MRXNPFEDSA-N 0.000 claims 1
- KEMAQYFMSWCNPP-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N4CC(O)C4)C=NN3C=C2)CCC1 KEMAQYFMSWCNPP-MRXNPFEDSA-N 0.000 claims 1
- DIVNKYZMVMAVDL-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound CC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N4CC(O)C4)C=NN3C=C2)CCC1 DIVNKYZMVMAVDL-QGZVFWFLSA-N 0.000 claims 1
- ZBAKBPQBWVZHSS-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound C1C(C)(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 ZBAKBPQBWVZHSS-MRXNPFEDSA-N 0.000 claims 1
- IAQOHRSJLFSNIO-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 IAQOHRSJLFSNIO-MRXNPFEDSA-N 0.000 claims 1
- ZTUAEBXOYDCUHH-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-methoxyazetidin-1-yl)methanone Chemical compound C1C(OC)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 ZTUAEBXOYDCUHH-QGZVFWFLSA-N 0.000 claims 1
- YWPVOJJFDPUXIP-DOTOQJQBSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-[(3s)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound C1[C@@H](O)CCN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 YWPVOJJFDPUXIP-DOTOQJQBSA-N 0.000 claims 1
- VCAFMQVDMYUXAD-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-[3-(hydroxymethyl)azetidin-1-yl]methanone Chemical compound C1C(CO)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 VCAFMQVDMYUXAD-QGZVFWFLSA-N 0.000 claims 1
- RFEWPNNVHIQMAM-GOSISDBHSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-piperidin-1-ylmethanone Chemical compound FC1=CN=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)N4CCCCC4)C=NN3C=C2)=C1 RFEWPNNVHIQMAM-GOSISDBHSA-N 0.000 claims 1
- VICTZKCFLVXPBL-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound FC1=CN=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)N4CCCC4)C=NN3C=C2)=C1 VICTZKCFLVXPBL-QGZVFWFLSA-N 0.000 claims 1
- CJXSUHUGXGYYSY-UHFFFAOYSA-N azetidin-1-yl-[5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone Chemical compound FC1=CN=CC(C2N(CCC2)C2=NC3=C(C(=O)N4CCC4)C=NN3C=C2)=C1 CJXSUHUGXGYYSY-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- IXPSNGNVZSOSLS-MRXNPFEDSA-N n-(1-fluoro-2-methylpropan-2-yl)-5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(CF)C)=CN=CC(F)=C1 IXPSNGNVZSOSLS-MRXNPFEDSA-N 0.000 claims 1
- HGBUMXKTCONBMP-FQNRMIAFSA-N n-(2,3-dihydroxypropyl)-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCC(O)CO)C=NN3C=C2)CCC1 HGBUMXKTCONBMP-FQNRMIAFSA-N 0.000 claims 1
- RWIYPTPMXPGFTG-CQSZACIVSA-N n-(2-chloroethyl)-5-[(2r)-2-(5-fluoro-2-oxo-1h-pyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CNC(=O)C([C@@H]2N(CCC2)C2=NC3=C(C(=O)NCCCl)C=NN3C=C2)=C1 RWIYPTPMXPGFTG-CQSZACIVSA-N 0.000 claims 1
- VMUKQRHNARMWLU-OAHLLOKOSA-N n-(3-aminopropyl)-5-[(2r)-2-(5-fluoro-2-oxo-1h-pyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NCCCN)=CC(F)=CNC1=O VMUKQRHNARMWLU-OAHLLOKOSA-N 0.000 claims 1
- ZOHMFCHQNJCASG-RHSMWYFYSA-N n-[(2r)-2,3-dihydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@@H](O)CO)C=NN3C=C2)CCC1 ZOHMFCHQNJCASG-RHSMWYFYSA-N 0.000 claims 1
- IVHDXWQQZJTUMV-CXAGYDPISA-N n-[(2r)-2,3-dihydroxypropyl]-5-[(2r)-2-[5-fluoro-2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC[C@@H](O)CO)=CC(F)=CC=C1C(F)(F)F IVHDXWQQZJTUMV-CXAGYDPISA-N 0.000 claims 1
- ZOHMFCHQNJCASG-WMLDXEAASA-N n-[(2s)-2,3-dihydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@H](O)CO)C=NN3C=C2)CCC1 ZOHMFCHQNJCASG-WMLDXEAASA-N 0.000 claims 1
- HGBUMXKTCONBMP-XJKSGUPXSA-N n-[(2s)-2,3-dihydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@H](O)CO)C=NN3C=C2)CCC1 HGBUMXKTCONBMP-XJKSGUPXSA-N 0.000 claims 1
- IVHDXWQQZJTUMV-SUMWQHHRSA-N n-[(2s)-2,3-dihydroxypropyl]-5-[(2r)-2-[5-fluoro-2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC[C@H](O)CO)=CC(F)=CC=C1C(F)(F)F IVHDXWQQZJTUMV-SUMWQHHRSA-N 0.000 claims 1
- FZWUREXRAHZCKC-CZUORRHYSA-N n-[(2s)-3-chloro-2-hydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@H](O)CCl)C=NN3C=C2)CCC1 FZWUREXRAHZCKC-CZUORRHYSA-N 0.000 claims 1
- PKQNMQSZDCVFLD-GOSISDBHSA-N n-cyclobutyl-5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CCC4)C=NN3C=C2)CCC1 PKQNMQSZDCVFLD-GOSISDBHSA-N 0.000 claims 1
- QVEBEDUBSUAZSH-UHFFFAOYSA-N n-cyclobutyl-5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CN=CC(C2N(CCC2)C2=NC3=C(C(=O)NC4CCC4)C=NN3C=C2)=C1 QVEBEDUBSUAZSH-UHFFFAOYSA-N 0.000 claims 1
- FUZYGEZQKAHUFX-QGZVFWFLSA-N n-cyclopropyl-5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CC=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 FUZYGEZQKAHUFX-QGZVFWFLSA-N 0.000 claims 1
- MQONFTAVRMZHBN-QGZVFWFLSA-N n-cyclopropyl-5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 MQONFTAVRMZHBN-QGZVFWFLSA-N 0.000 claims 1
- JKTPHVQLCMLNMW-MRXNPFEDSA-N n-cyclopropyl-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 JKTPHVQLCMLNMW-MRXNPFEDSA-N 0.000 claims 1
- ZBJDRRTVBWHVAP-MRXNPFEDSA-N n-cyclopropyl-5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CN=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 ZBJDRRTVBWHVAP-MRXNPFEDSA-N 0.000 claims 1
- ZGPOATYOAANSTK-LRTDYKAYSA-N n-cyclopropyl-5-[(2r)-2-[2-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(O)COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 ZGPOATYOAANSTK-LRTDYKAYSA-N 0.000 claims 1
- SVIHXEVVNNRVEM-BDPMCISCSA-N n-cyclopropyl-5-[(2r)-2-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 SVIHXEVVNNRVEM-BDPMCISCSA-N 0.000 claims 1
- YDZSAJWQPHVDHL-UUSAFJCLSA-N n-cyclopropyl-5-[(2r)-2-[3-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(O)COC1=CC(F)=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 YDZSAJWQPHVDHL-UUSAFJCLSA-N 0.000 claims 1
- HLAYAPGHRGSWFL-LWMIZPGFSA-N n-cyclopropyl-5-[(2r)-2-[3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC(F)=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 HLAYAPGHRGSWFL-LWMIZPGFSA-N 0.000 claims 1
- DXRCURBJOZPWHE-JOCHJYFZSA-N n-cyclopropyl-5-[(2r)-2-[5-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=CC(F)=CC=C1OCCN1CCOCC1 DXRCURBJOZPWHE-JOCHJYFZSA-N 0.000 claims 1
- DHEFBJXZYSKWIF-NVXWUHKLSA-N n-cyclopropyl-5-[(2r,4r)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N1([C@H](C[C@H](C1)O)C=1C=C(F)C=CC=1)C(=NC1=2)C=CN1N=CC=2C(=O)NC1CC1 DHEFBJXZYSKWIF-NVXWUHKLSA-N 0.000 claims 1
- HQCZHKJSSABUNL-GOSISDBHSA-N n-cyclopropyl-5-[(5r)-5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N1([C@H](CCC1(C)C)C=1C(=CC=C(F)C=1)F)C(=NC1=2)C=CN1N=CC=2C(=O)NC1CC1 HQCZHKJSSABUNL-GOSISDBHSA-N 0.000 claims 1
- HNJJBTOZBLOWTO-UHFFFAOYSA-N n-cyclopropyl-5-[2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CCC1=NC=C(F)C=C1C1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 HNJJBTOZBLOWTO-UHFFFAOYSA-N 0.000 claims 1
- XCCJJNIKWGXTSP-UHFFFAOYSA-N n-cyclopropyl-5-[2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=NC=C(F)C=C1C1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 XCCJJNIKWGXTSP-UHFFFAOYSA-N 0.000 claims 1
- XDTRTPIHJGKMHO-QGZVFWFLSA-N n-tert-butyl-5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CC(F)=CC=C1F XDTRTPIHJGKMHO-QGZVFWFLSA-N 0.000 claims 1
- CABSRBXIZHPYSN-MRXNPFEDSA-N n-tert-butyl-5-[(2r)-2-(5-fluoro-1-methyl-2-oxopyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C1N(C)C=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC(C)(C)C)C=NN3C=C2)CCC1 CABSRBXIZHPYSN-MRXNPFEDSA-N 0.000 claims 1
- ACAZGFYJHFUFNU-MRXNPFEDSA-N n-tert-butyl-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC(C)(C)C)C=NN3C=C2)CCC1 ACAZGFYJHFUFNU-MRXNPFEDSA-N 0.000 claims 1
- SPGMDULIPMJULM-OAHLLOKOSA-N n-tert-butyl-5-[(2r)-2-(5-fluoro-2-oxo-1h-pyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CC(F)=CNC1=O SPGMDULIPMJULM-OAHLLOKOSA-N 0.000 claims 1
- BOGXBCHXRCHFDS-MRXNPFEDSA-N n-tert-butyl-5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CN=CC(F)=C1 BOGXBCHXRCHFDS-MRXNPFEDSA-N 0.000 claims 1
- JSSACTCBXIXNAA-NVXWUHKLSA-N n-tert-butyl-5-[(2r,4r)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2C[C@@H](O)CN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CC=CC(F)=C1 JSSACTCBXIXNAA-NVXWUHKLSA-N 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- LKKQICCORQINHH-UHFFFAOYSA-N 3-fluoro-3H-pyridin-6-one Chemical group FC1C=CC(=O)N=C1 LKKQICCORQINHH-UHFFFAOYSA-N 0.000 description 4
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22419609P | 2009-07-09 | 2009-07-09 | |
| US61/224,196 | 2009-07-09 | ||
| US34676710P | 2010-05-20 | 2010-05-20 | |
| US61/346,767 | 2010-05-20 | ||
| PCT/US2010/041538 WO2011006074A1 (en) | 2009-07-09 | 2010-07-09 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002767A Division JP6114765B2 (ja) | 2009-07-09 | 2015-01-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532888A JP2012532888A (ja) | 2012-12-20 |
| JP2012532888A5 true JP2012532888A5 (enExample) | 2013-08-08 |
| JP5716021B2 JP5716021B2 (ja) | 2015-05-13 |
Family
ID=42732102
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519764A Expired - Fee Related JP5716021B2 (ja) | 2009-07-09 | 2010-07-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP2015002767A Expired - Fee Related JP6114765B2 (ja) | 2009-07-09 | 2015-01-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP2017020927A Withdrawn JP2017082004A (ja) | 2009-07-09 | 2017-02-08 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002767A Expired - Fee Related JP6114765B2 (ja) | 2009-07-09 | 2015-01-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP2017020927A Withdrawn JP2017082004A (ja) | 2009-07-09 | 2017-02-08 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US8791123B2 (enExample) |
| EP (2) | EP3299372B1 (enExample) |
| JP (3) | JP5716021B2 (enExample) |
| KR (3) | KR101784977B1 (enExample) |
| CN (3) | CN110003214B (enExample) |
| AR (1) | AR077468A1 (enExample) |
| AU (1) | AU2010271270C1 (enExample) |
| CA (2) | CA2767648C (enExample) |
| CL (1) | CL2012000059A1 (enExample) |
| CO (1) | CO6612183A2 (enExample) |
| CR (2) | CR20120065A (enExample) |
| ES (2) | ES2655899T3 (enExample) |
| IL (1) | IL217414A (enExample) |
| MX (2) | MX364157B (enExample) |
| MY (1) | MY162180A (enExample) |
| NZ (1) | NZ598086A (enExample) |
| RU (2) | RU2016114128A (enExample) |
| SG (2) | SG10201603095TA (enExample) |
| TW (1) | TWI503321B (enExample) |
| UY (1) | UY32782A (enExample) |
| WO (1) | WO2011006074A1 (enExample) |
| ZA (1) | ZA201200982B (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| BRPI0924084B1 (pt) | 2008-12-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina e composição farmacêutica que os compreende |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| AU2012220572A1 (en) * | 2011-02-25 | 2013-08-29 | Irm Llc | Compounds and compositions as trk inhibitors |
| KR102001364B1 (ko) | 2011-05-13 | 2019-07-22 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
| IN2014CN02501A (enExample) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| IN2014DN07384A (enExample) * | 2012-03-09 | 2015-04-24 | Lexicon Pharmaceuticals Inc | |
| US20140044802A1 (en) | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| UA116455C2 (uk) * | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| BR122017003188A2 (pt) * | 2013-02-19 | 2019-09-10 | Ono Pharmaceutical Co | composto 1-{2-[4-(2-amino-5-cloro-3-piridinil)fenóxi]-5-pirimidinil}-3-[2-(metilsulfonil)-5-(trifluorometil)fenil]ureia, sal deste, composição farmacêutica compreendendo-os e uso destes para o tratamento de câncer |
| SI2989106T1 (sl) | 2013-04-25 | 2017-07-31 | Beigene, Ltd. | Zlite heterociklične spojine kot inhibitorji beljakovinske kinaze |
| WO2015017533A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
| TWI663159B (zh) * | 2013-12-10 | 2019-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| WO2015104602A2 (en) | 2014-01-08 | 2015-07-16 | Wockhardt Limited | A process for the preparation of anagliptin and its intermediates thereof |
| AU2015209239C1 (en) | 2014-01-24 | 2026-05-07 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| WO2015150887A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Process for the preparation of anagliptin or its salts |
| US20150324646A1 (en) | 2014-05-08 | 2015-11-12 | Brown University | Navigation methods and apparatus for the visually impaired |
| MY191956A (en) | 2014-05-15 | 2022-07-20 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| EA032488B1 (ru) | 2014-05-23 | 2019-06-28 | Ф. Хоффманн-Ля Рош Аг | Соединения 5-хлор-дифторметоксифенилпиразолопиримидина, представляющие собой ингибиторы янус-киназы |
| AP2016009487A0 (en) | 2014-05-28 | 2016-10-31 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| CN106573913B (zh) | 2014-08-18 | 2019-11-19 | 小野药品工业株式会社 | 抑制Trk的化合物的酸加成盐 |
| HRP20192334T1 (hr) * | 2014-09-17 | 2020-03-20 | Oncodesign S.A. | Makrociklički inhibitori kinaze rip2 |
| CN107001379B (zh) | 2014-11-06 | 2022-11-01 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| ES2983908T3 (es) * | 2014-12-15 | 2024-10-28 | Cmg Pharmaceutical Co Ltd | Compuestos heteroarílicos de anillo condensado y su uso como inhibidores de TRK |
| KR20180021745A (ko) | 2015-06-01 | 2018-03-05 | 록쏘 온콜로지, 인코포레이티드 | 암을 진단하고 치료하는 방법 |
| MX2017017097A (es) | 2015-07-02 | 2018-05-23 | Tp Therapeutics Inc | Macrociclos diarílicos quirales como moduladores de proteínas quinasas. |
| PL3319969T3 (pl) | 2015-07-06 | 2024-06-24 | Turning Point Therapeutics, Inc. | Diarylowe polimorfy makrocykliczne |
| HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
| LT3733187T (lt) | 2015-07-21 | 2024-12-10 | Turning Point Therapeutics, Inc. | Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui |
| CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| WO2017073706A1 (ja) * | 2015-10-30 | 2017-05-04 | 中外製薬株式会社 | ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体 |
| MX2018006195A (es) * | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| ES2987501T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Métodos de tratamiento de cánceres pediátricos |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017176960A1 (en) * | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| MX389579B (es) | 2016-05-05 | 2025-03-20 | Bial R&D Invest S A | IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| EP4509183A3 (en) | 2016-08-16 | 2025-05-21 | BeiGene Switzerland GmbH | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| AU2017313085B2 (en) | 2016-08-19 | 2024-06-20 | Beone Medicines I Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
| KR101881650B1 (ko) * | 2016-10-02 | 2018-07-24 | 재단법인대구경북과학기술원 | 뇌유래신경성장인자를 과발현하는 우울증 동물모델 및 이의 제조방법 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| EP3533796B1 (en) | 2016-10-28 | 2021-09-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
| CN108003161B (zh) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 神经营养因子酪氨酸激酶受体抑制剂 |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| CN109824566A (zh) * | 2017-07-19 | 2019-05-31 | 浙江师范大学 | 一种(r)-2-(2,5-二氟苯基)吡咯烷的合成方法 |
| WO2019023468A1 (en) * | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| US11344553B2 (en) * | 2017-08-11 | 2022-05-31 | Teligene Ltd. | Substituted pyrazolopyrimidines useful as kinases inhibitors |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| RS66124B1 (sr) | 2017-12-15 | 2024-11-29 | Biohaven Therapeutics Ltd | Derivati 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina i srodna jedinjenja kao inhibitori trk kinaze za lečenje kancera |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| AU2019233204B2 (en) * | 2018-03-14 | 2022-02-03 | Fochon Biosciences, Ltd. | Substituted (2-azabicyclo (3.1.0) hexan-2-yl) pyrazolo (1, 5-a) pyrimidine and imidazo (1, 2-b) pyridazine compounds as TRK kinases inhibitors |
| CA3095366A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| US12129258B2 (en) | 2018-04-25 | 2024-10-29 | Primegene (Beijing) Co., Ltd | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
| CN110294761B (zh) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| AU2019323446B2 (en) | 2018-08-22 | 2025-01-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| PL3842431T3 (pl) * | 2018-08-23 | 2024-05-20 | Zhuhai United Laboratories Co., Ltd. | Związek [1,2,4]triazolo[1,5-a]pirydyny jako inhibitor jak i jego zastosowanie |
| CN110857304B (zh) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk抑制剂、其制备方法和用途 |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| CA3115088A1 (en) * | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| US20210395256A1 (en) * | 2018-12-07 | 2021-12-23 | Betta Pharmaceuticals Co., Ltd. | Tyrosine kinase inhibitors, compositions and methods there of |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| US12527776B2 (en) | 2019-02-04 | 2026-01-20 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) |
| SG11202107589PA (en) | 2019-02-22 | 2021-08-30 | Regeneron Pharma | Rodents having genetically modified sodium channels and methods of use thereof |
| CN111718351B (zh) * | 2019-03-19 | 2021-10-12 | 华中师范大学 | 含氧取代吡唑并嘧啶化合物和药物组合物及其应用 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN111848626B (zh) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | Trk激酶抑制剂及其用途 |
| AU2020270303B2 (en) * | 2019-05-08 | 2023-09-07 | Tyk Medicines, Inc. | Compound used as kinase inhibitor and application thereof |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| KR20210061202A (ko) | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| CN111138437B (zh) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途 |
| JP2023504866A (ja) * | 2019-12-13 | 2023-02-07 | ▲賽▼▲諾▼哈勃▲薬▼▲業▼（成都）有限公司 | 大環構造を有するフッ素含有複素環誘導体およびその用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021148010A1 (zh) * | 2020-01-22 | 2021-07-29 | 南京明德新药研发有限公司 | 吡唑并杂芳环类化合物及其应用 |
| EP4100009A1 (en) | 2020-02-03 | 2022-12-14 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| US12419873B2 (en) * | 2020-02-13 | 2025-09-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
| JP7692924B2 (ja) | 2020-02-26 | 2025-06-16 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| CN114437077B (zh) * | 2020-11-04 | 2024-01-30 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
| BR112022022437A2 (pt) | 2020-05-07 | 2023-01-03 | Adorx Therapeutics Ltd | Antagonistas do receptor a2a de adenosina |
| US12617797B2 (en) | 2020-05-27 | 2026-05-05 | Esteve Pharmaceuticals, S.A. | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain |
| CN115551863A (zh) * | 2020-06-11 | 2022-12-30 | 贝达药业股份有限公司 | 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途 |
| CN111777549A (zh) * | 2020-07-07 | 2020-10-16 | 中瀚(齐河县)生物医药科技有限公司 | 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺 |
| KR20230043024A (ko) | 2020-07-24 | 2023-03-30 | 젠자임 코포레이션 | 벤글루스타트를 포함하는 제약 조성물 |
| CN113563343B (zh) * | 2020-07-27 | 2022-05-24 | 杭州邦顺制药有限公司 | 取代的吡唑并[1,5-a]嘧啶化合物及其用途 |
| CN112645955B (zh) * | 2020-12-24 | 2022-11-04 | 四川国康药业有限公司 | 一种[1,2,4]三唑并[4,3-b]哒嗪类化合物及其制备方法和用途 |
| WO2022150584A1 (en) * | 2021-01-08 | 2022-07-14 | Yale University | Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use |
| CN115867553B (zh) | 2021-01-09 | 2026-03-06 | 巴格沃克斯研究有限公司 | 作为腺苷2A受体和腺苷2B受体拮抗剂的二氨基吡唑[1, 5-a]并嘧啶-6-腈化合物 |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| CN116115618B (zh) * | 2021-11-15 | 2025-07-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗肿瘤的药物 |
| CN114907247A (zh) * | 2022-04-21 | 2022-08-16 | 上海陶术生物科技有限公司 | 吡咯烷中间体及吡咯烷盐类化合物的制备方法 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| WO2025107298A1 (zh) * | 2023-11-24 | 2025-05-30 | 浙江同源康医药股份有限公司 | 晶体、药物组合物及其制备方法和应用 |
Family Cites Families (255)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234143A (en) | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
| RO118291B1 (ro) | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
| CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
| JP3898296B2 (ja) | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
| EP0979231B1 (en) | 1997-04-25 | 2004-11-24 | Takeda Chemical Industries, Ltd. | Condensed pyridazine derivatives, their production and use |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6534085B1 (en) | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
| IL153375A0 (en) | 2000-06-22 | 2003-07-06 | Genentech Inc | Agonist anti-trk-c monoclonal antibodies |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| EP2340849A1 (en) | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| KR20040097375A (ko) | 2002-04-23 | 2004-11-17 | 시오노기 앤드 컴파니, 리미티드 | 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제 |
| US7449488B2 (en) | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| ITMI20021620A1 (it) | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
| JP4024624B2 (ja) * | 2002-08-26 | 2007-12-19 | 富士通株式会社 | 半導体装置の製造方法及び製造装置 |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| CN100376580C (zh) * | 2002-09-04 | 2008-03-26 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7262199B2 (en) | 2002-12-11 | 2007-08-28 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| DE602004021472D1 (en) | 2003-02-20 | 2009-07-23 | Smithkline Beecham Corp | Pyrimiidinverbindungen |
| WO2004082458A2 (en) | 2003-02-21 | 2004-09-30 | The Johns Hopkins University | Tyrosine kinome |
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| EP1619203A1 (en) | 2003-04-28 | 2006-01-25 | Galpharma Co., Ltd. | Galectin 9-inducing factor |
| PA8603801A1 (es) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| JP2005008581A (ja) * | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| EA009517B1 (ru) | 2003-06-27 | 2008-02-28 | Байер Кропсайенс Аг | Пиразолопиримидины |
| MEP31508A (hr) | 2003-07-15 | 2010-10-10 | Amgen Inc | Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2005044835A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| DE602004012891T2 (de) | 2003-12-18 | 2009-04-09 | Janssen Pharmaceutica N.V. | Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel |
| PL1696920T3 (pl) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
| WO2005068424A1 (en) | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
| UA91677C2 (ru) | 2004-03-30 | 2010-08-25 | Интермюн, Инк. | Макроциклические соединения как ингибиторы вирусной репликации |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| ES2354824T3 (es) | 2004-11-04 | 2011-03-18 | Vertex Pharmaceuticals, Inc. | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. |
| JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| WO2006087538A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| PT1869049E (pt) | 2005-03-21 | 2009-05-26 | Lilly Co Eli | Compostos de imidazopiridazina |
| US20090005396A1 (en) | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
| JP2008540622A (ja) | 2005-05-16 | 2008-11-20 | アストラゼネカ アクチボラグ | 化合物 |
| CN100406650C (zh) | 2005-06-05 | 2008-07-30 | 徐斌 | 一种抗特大变位的模块式梳型桥梁伸缩缝装置 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| US20070025540A1 (en) | 2005-07-07 | 2007-02-01 | Roger Travis | Call center routing based on talkativeness |
| JP5249028B2 (ja) | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規大環状阻害剤 |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| US20070184117A1 (en) | 2005-08-03 | 2007-08-09 | Stephen Gregory | Tocopheryl polyethylene glycol succinate powder and process for preparing same |
| WO2007024680A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| HRP20140218T4 (hr) | 2005-08-25 | 2017-06-16 | Creabilis Therapeutics S.P.A. | Polimerni konjugati k-252a i njihovi derivati |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| CN101316847A (zh) | 2005-10-06 | 2008-12-03 | 先灵公司 | 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物 |
| GEP20104956B (en) | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
| US7880021B2 (en) | 2005-10-11 | 2011-02-01 | Centre National De La Recherche Scientifique (Cnrs) | Compounds and kits for the detection and the quantification of cell apoptosis |
| WO2007048064A2 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Amino-pyrimidines as casein kinase ii (ck2) modulators |
| WO2007057399A2 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| WO2007077435A1 (en) | 2005-12-30 | 2007-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20080108611A1 (en) | 2006-01-19 | 2008-05-08 | Battista Kathleen A | Substituted thienopyrimidine kinase inhibitors |
| WO2007087245A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Ret tyrosine kinase inhibition |
| KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| MX2008011220A (es) | 2006-03-07 | 2008-09-11 | Array Biopharma Inc | Compuestos de pirazol heterobiciclicos y metodos de uso. |
| UA94097C2 (ru) | 2006-03-27 | 2011-04-11 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ |
| GB0606805D0 (en) | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
| RU2439074C2 (ru) | 2006-04-26 | 2012-01-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К) |
| WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| US7389632B2 (en) | 2006-06-10 | 2008-06-24 | Uhlmann Pac-Systeme Gmbh & Co. Kg | Apparatus for distributing small objects in a fill station |
| EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| TWI419889B (zh) * | 2006-07-05 | 2013-12-21 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔１，５-ａ〕嘧啶化合物 |
| US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
| US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| EP2067039A2 (en) | 2006-09-12 | 2009-06-10 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research | Non-neuroendocrine cancer therapy |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| KR20090075714A (ko) | 2006-10-30 | 2009-07-08 | 노파르티스 아게 | 소염제로서의 헤테로시클릭 화합물 |
| MY146474A (en) | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008080015A2 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| EP2137187A1 (en) | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| NZ580327A (en) | 2007-04-03 | 2012-02-24 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| EP2152688A1 (en) | 2007-05-04 | 2010-02-17 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| DK2170827T3 (da) | 2007-06-21 | 2013-11-18 | Janssen Pharmaceutica Nv | Indolin-2-oner og aza-indolin-2-oner |
| BRPI0814818A2 (pt) | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009014637A2 (en) | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
| US8299057B2 (en) | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| MY161564A (en) | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| CA2702838A1 (en) | 2007-10-16 | 2009-04-23 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| EA201000603A1 (ru) | 2007-10-23 | 2010-12-30 | Новартис Аг | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ |
| WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| CA2706946A1 (en) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| JP5400791B2 (ja) | 2007-12-04 | 2014-01-29 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用 |
| CL2009000090A1 (es) | 2008-01-17 | 2009-07-24 | Irm Llc | Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. |
| US20090227556A1 (en) | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| WO2009118411A2 (en) | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP2300469B1 (en) | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| US8119637B2 (en) | 2008-06-10 | 2012-02-21 | Plexxikon Inc. | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor |
| WO2010012733A1 (en) | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | Use of a cdk inhibitor for the treatment of glioma |
| EP2376492B1 (en) | 2008-09-19 | 2015-04-08 | Nerviano Medical Sciences S.r.l. | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES |
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| WO2010058006A1 (en) | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor for the treatment of mesothelioma |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| JP5979877B2 (ja) | 2009-02-12 | 2016-08-31 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト癌における変異ｒｏｓ発現 |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| WO2010145998A1 (en) | 2009-06-15 | 2010-12-23 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2528918B1 (en) | 2010-01-29 | 2014-09-10 | Nerviano Medical Sciences S.r.l. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
| ES2594927T3 (es) | 2010-02-18 | 2016-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para prevenir las metástasis cancerosas |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| US8543395B2 (en) | 2010-05-18 | 2013-09-24 | Shazam Entertainment Ltd. | Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| RU2591191C2 (ru) | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
| US8916577B2 (en) | 2011-01-26 | 2014-12-23 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
| MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| AU2012220572A1 (en) | 2011-02-25 | 2013-08-29 | Irm Llc | Compounds and compositions as trk inhibitors |
| WO2012139930A1 (en) | 2011-04-11 | 2012-10-18 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| BR112013026137B1 (pt) | 2011-04-19 | 2020-12-01 | Nerviano Medical Sciences S.R.L | pirimidinil-pirróis substituídos ativos como inibidores da quinase |
| CA2835478C (en) | 2011-05-12 | 2019-02-05 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| KR102001364B1 (ko) | 2011-05-13 | 2019-07-22 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
| EP2736514B1 (en) | 2011-07-28 | 2017-10-18 | Nerviano Medical Sciences S.r.l. | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| US9181258B2 (en) | 2011-10-07 | 2015-11-10 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| WO2013074518A1 (en) | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| BR112014014276A2 (pt) | 2011-12-12 | 2017-06-13 | Dr Reddys Laboratories Ltd | composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US9242977B2 (en) | 2012-04-26 | 2016-01-26 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| JP2013226108A (ja) | 2012-04-27 | 2013-11-07 | Astellas Pharma Inc | 新規ｎｔｒｋ２活性化変異の検出法 |
| KR102151963B1 (ko) | 2012-05-23 | 2020-09-07 | 네르비아노 메디칼 사이언시스 에스.알.엘. | Ｎ-[5-(3,5-디플루오로-벤질)-1ｈ-인다졸-3-일]-4-(4-메틸-피페라진-1-일)-2-(테트라하이드로-피란-4-일아미노)-벤즈아미드의 제조 방법 |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| DK2880025T3 (en) | 2012-08-02 | 2019-03-18 | Nerviano Medical Sciences Srl | SUBSTITUTED PYROLES ACTIVE AS KINase INHIBITORS |
| US20150218652A1 (en) | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
| EP2892532B1 (en) | 2012-09-07 | 2019-02-13 | Exelixis, Inc. | Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma |
| US20140084039A1 (en) | 2012-09-24 | 2014-03-27 | Electro Scientific Industries, Inc. | Method and apparatus for separating workpieces |
| JP2014082984A (ja) | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | 新規ｎｔｒｋ２活性化変異の検出法 |
| AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
| WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| UA116455C2 (uk) | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| EP2925359A2 (en) | 2012-11-29 | 2015-10-07 | Yeda Research and Development Co., Ltd. | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
| US9447135B2 (en) | 2012-12-14 | 2016-09-20 | University Of Kentucky Research Foundation | Semi-synthetic mithramycin derivatives with anti-cancer activity |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| BR122017003188A2 (pt) | 2013-02-19 | 2019-09-10 | Ono Pharmaceutical Co | composto 1-{2-[4-(2-amino-5-cloro-3-piridinil)fenóxi]-5-pirimidinil}-3-[2-(metilsulfonil)-5-(trifluorometil)fenil]ureia, sal deste, composição farmacêutica compreendendo-os e uso destes para o tratamento de câncer |
| EP2981613A4 (en) | 2013-02-22 | 2016-11-02 | Boris C Bastian | FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES RELATED TO CANCER AND IN PARTICULAR TO MELANOMA AND USES THEREOF AS THERAPEUTIC AND DIAGNOSTIC OBJECTIVES |
| US20140243332A1 (en) | 2013-02-27 | 2014-08-28 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
| ES2900301T3 (es) | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
| CN113337604A (zh) | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
| MA38394B1 (fr) | 2013-03-15 | 2018-04-30 | Glaxosmithkline Ip Dev Ltd | Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| WO2014152777A2 (en) | 2013-03-15 | 2014-09-25 | Insight Genetics, Inc. | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| AU2014254394B2 (en) | 2013-04-17 | 2020-06-18 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
| US10072298B2 (en) | 2013-04-17 | 2018-09-11 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
| US9682083B2 (en) | 2013-05-14 | 2017-06-20 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| AU2014274093B2 (en) | 2013-05-30 | 2018-11-08 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| JP6510510B2 (ja) | 2013-07-11 | 2019-05-08 | ベータ ファーマシューティカルズ カンパニー リミテッド | プロテインチロシンキナーゼモジュレーター及び使用方法 |
| WO2015012397A1 (ja) | 2013-07-26 | 2015-01-29 | 公益財団法人がん研究会 | Ｎｔｒｋ３融合体の検出法 |
| EP3027654B1 (en) | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
| WO2015017533A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
| WO2015039006A1 (en) | 2013-09-16 | 2015-03-19 | The General Hospital Corporation | Methods of treating cancer |
| LT3057969T (lt) | 2013-10-17 | 2018-07-10 | Blueprint Medicines Corporation | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| RU2016114498A (ru) | 2013-10-24 | 2017-11-29 | Джорджтаун Юниверсити | Способы и композиции для лечения раковых заболеваний |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015064621A1 (ja) | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| AU2015209239C1 (en) | 2014-01-24 | 2026-05-07 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| WO2015120136A1 (en) | 2014-02-05 | 2015-08-13 | VM Oncology LLC | Compositions of compounds and uses thereof |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| EP3132054B1 (en) | 2014-04-18 | 2021-06-30 | Blueprint Medicines Corporation | Met fusions |
| EP3132056B1 (en) | 2014-04-18 | 2021-11-24 | Blueprint Medicines Corporation | Pik3ca fusions |
| MY191956A (en) | 2014-05-15 | 2022-07-20 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| WO2015183837A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
| WO2015183836A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
| WO2015184443A1 (en) | 2014-05-30 | 2015-12-03 | The Regents Of The University Of Colorado | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
| US10378063B2 (en) | 2014-06-10 | 2019-08-13 | Blueprint Medicines Corporation | RAF1 fusions |
| US10246750B2 (en) | 2014-06-10 | 2019-04-02 | Blueprint Medicines Corporation | Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion |
| US10370723B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | TERT fusions |
| EP3169804B3 (en) | 2014-07-17 | 2019-09-18 | Blueprint Medicines Corporation | Fgr fusions |
| WO2016011147A1 (en) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Prkc fusions |
| SG11201700774UA (en) | 2014-08-01 | 2017-02-27 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CN106573913B (zh) | 2014-08-18 | 2019-11-19 | 小野药品工业株式会社 | 抑制Trk的化合物的酸加成盐 |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| KR102562866B1 (ko) | 2014-11-14 | 2023-08-04 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| EP3221700B1 (en) | 2014-11-18 | 2022-06-22 | Blueprint Medicines Corporation | Prkacb fusions |
| ES2983908T3 (es) | 2014-12-15 | 2024-10-28 | Cmg Pharmaceutical Co Ltd | Compuestos heteroarílicos de anillo condensado y su uso como inhibidores de TRK |
| CA2986235A1 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute, Inc. | Shared neoantigens |
| AU2016270321B2 (en) | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
| KR20180021745A (ko) | 2015-06-01 | 2018-03-05 | 록쏘 온콜로지, 인코포레이티드 | 암을 진단하고 치료하는 방법 |
| AU2015101722A4 (en) | 2015-06-19 | 2016-05-19 | Macau University Of Science And Technology | Oncogenic ros1 and alk kinase inhibitor |
| US9782400B2 (en) | 2015-06-19 | 2017-10-10 | Macau University Of Science And Technology | Oncogenic ROS1 and ALK kinase inhibitor |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MX2017017097A (es) | 2015-07-02 | 2018-05-23 | Tp Therapeutics Inc | Macrociclos diarílicos quirales como moduladores de proteínas quinasas. |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US20170224662A1 (en) | 2016-01-22 | 2017-08-10 | The Medicines Company | Aqueous Formulations and Methods of Preparation and Use Thereof |
| WO2017155018A1 (ja) | 2016-03-11 | 2017-09-14 | 小野薬品工業株式会社 | Ｔｒｋ阻害剤抵抗性の癌治療剤 |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US20210030737A1 (en) | 2016-04-19 | 2021-02-04 | Exelixis, Inc. | Triple Negative Breast Cancer Treatment Method |
| WO2017201156A1 (en) | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
-
2010
- 2010-07-08 AR ARP100102489A patent/AR077468A1/es not_active Application Discontinuation
- 2010-07-09 US US13/382,858 patent/US8791123B2/en active Active
- 2010-07-09 MX MX2015000539A patent/MX364157B/es unknown
- 2010-07-09 CN CN201811635133.0A patent/CN110003214B/zh not_active Expired - Fee Related
- 2010-07-09 SG SG10201603095TA patent/SG10201603095TA/en unknown
- 2010-07-09 ES ES10732606.8T patent/ES2655899T3/es active Active
- 2010-07-09 RU RU2016114128A patent/RU2016114128A/ru not_active Application Discontinuation
- 2010-07-09 ES ES17199899T patent/ES2774654T3/es active Active
- 2010-07-09 MX MX2012000513A patent/MX2012000513A/es active IP Right Grant
- 2010-07-09 NZ NZ598086A patent/NZ598086A/en not_active IP Right Cessation
- 2010-07-09 MY MYPI2012000087A patent/MY162180A/en unknown
- 2010-07-09 KR KR1020127003458A patent/KR101784977B1/ko not_active Expired - Fee Related
- 2010-07-09 CA CA2767648A patent/CA2767648C/en active Active
- 2010-07-09 CN CN201080040095.XA patent/CN102596957B/zh not_active Expired - Fee Related
- 2010-07-09 KR KR1020187037088A patent/KR101997055B1/ko not_active Expired - Fee Related
- 2010-07-09 TW TW099122737A patent/TWI503321B/zh not_active IP Right Cessation
- 2010-07-09 EP EP17199899.0A patent/EP3299372B1/en active Active
- 2010-07-09 WO PCT/US2010/041538 patent/WO2011006074A1/en not_active Ceased
- 2010-07-09 AU AU2010271270A patent/AU2010271270C1/en not_active Ceased
- 2010-07-09 CN CN201610388362.1A patent/CN106008523B/zh not_active Expired - Fee Related
- 2010-07-09 CA CA3013618A patent/CA3013618C/en active Active
- 2010-07-09 UY UY0001032782A patent/UY32782A/es not_active Application Discontinuation
- 2010-07-09 KR KR1020177027763A patent/KR101933123B1/ko not_active Expired - Fee Related
- 2010-07-09 RU RU2012104493/04A patent/RU2584157C2/ru not_active IP Right Cessation
- 2010-07-09 JP JP2012519764A patent/JP5716021B2/ja not_active Expired - Fee Related
- 2010-07-09 SG SG2012001178A patent/SG177553A1/en unknown
- 2010-07-09 EP EP10732606.8A patent/EP2451812B1/en active Active
-
2012
- 2012-01-08 IL IL217414A patent/IL217414A/en not_active IP Right Cessation
- 2012-01-09 CL CL2012000059A patent/CL2012000059A1/es unknown
- 2012-02-08 CR CR20120065A patent/CR20120065A/es unknown
- 2012-02-08 CO CO12022116A patent/CO6612183A2/es active IP Right Grant
- 2012-02-09 ZA ZA2012/00982A patent/ZA201200982B/en unknown
- 2012-12-17 CR CR20120641A patent/CR20120641A/es unknown
-
2014
- 2014-07-01 US US14/321,246 patent/US9682979B2/en active Active
-
2015
- 2015-01-09 JP JP2015002767A patent/JP6114765B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-09 US US15/401,913 patent/US9782415B2/en active Active
- 2017-01-09 US US15/401,895 patent/US9796724B2/en active Active
- 2017-02-08 JP JP2017020927A patent/JP2017082004A/ja not_active Withdrawn
- 2017-10-04 US US15/724,601 patent/US10251889B2/en active Active
-
2019
- 2019-04-08 US US16/377,514 patent/US10758542B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012104493A (ru) | Замещенные соединения пиразоло [1,5-a] пиримидина как ингибиторы киназы trk | |
| JP2012503018A5 (enExample) | ||
| JP2019537571A5 (enExample) | ||
| JP2021535134A5 (enExample) | ||
| RU2015154987A (ru) | Гетероциклические производные | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| JP2022520811A5 (enExample) | ||
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| JP2019533694A5 (enExample) | ||
| JP2019038820A5 (enExample) | ||
| JP2023536164A5 (enExample) | ||
| JP2017530999A5 (enExample) | ||
| JP2016517878A5 (enExample) | ||
| RU2016108753A (ru) | Ингибиторы ферментов | |
| RU2009101911A (ru) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы | |
| JP2011500806A5 (enExample) | ||
| JP2021512143A5 (enExample) | ||
| RU2016137674A (ru) | Производные пиперидиндиона | |
| JP2017525757A5 (enExample) | ||
| JP2013512900A5 (enExample) | ||
| JP2017505794A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2018516932A5 (enExample) |